Chemotherapeutics are known to upregulate PD-L1 in cancer cells, and the addition of an anti-PD1 antibody to platin-containing induction chemotherapy has proved to significantly increase the response rate in patients with non-small cell lung cancer [17,18]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.